Evaluation of Ovarian Reserve with AMH Level in Patients with Well-Differentiated Thyroid Cancer Receiving Radioactive Iodine Ablation Treatment


Acibucu F., Acibucu D. O. , Akkar O. B. , Dokmetas H. S.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, vol.124, no.10, pp.593-596, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 124 Issue: 10
  • Publication Date: 2016
  • Doi Number: 10.1055/s-0042-115639
  • Title of Journal : EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
  • Page Numbers: pp.593-596

Abstract

Introduction: Radioactive iodine (RAI) ablation treatment is used for patients diagnosed with well-differentiated thyroid cancer in order to reduce the risk of recurrence. RAI ablation treatment can adversely affect gonads in males and females. In this study, we aimed to determine ovary damage and infertility risk due to RAI, using serum anti-Mullerian hormone (AMH) level, in females who received RAI ablation treatment.